X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs STERLING BIOTECH - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA STERLING BIOTECH GLENMARK PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 13.9 -1.8 - View Chart
P/BV x 3.9 0.1 5,669.0% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 GLENMARK PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-16
STERLING BIOTECH
Dec-13
GLENMARK PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,26211 12,019.0%   
Low Rs6723 19,750.0%   
Sales per share (Unadj.) Rs270.626.8 1,009.3%  
Earnings per share (Unadj.) Rs24.9-15.0 -166.3%  
Cash flow per share (Unadj.) Rs34.4-5.5 -630.0%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs151.354.9 275.8%  
Shares outstanding (eoy) m282.16267.87 105.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.60.3 1,378.2%   
Avg P/E ratio x38.9-0.5 -8,363.4%  
P/CF ratio (eoy) x28.1-1.3 -2,208.0%  
Price / Book Value ratio x6.40.1 5,044.3%  
Dividend payout %8.00-   
Avg Mkt Cap Rs m272,7781,862 14,652.1%   
No. of employees `00010.01.4 740.4%   
Total wages/salary Rs m13,782547 2,520.5%   
Avg. sales/employee Rs Th7,614.95,303.3 143.6%   
Avg. wages/employee Rs Th1,374.8403.8 340.4%   
Avg. net profit/employee Rs Th700.2-2,959.0 -23.7%   
INCOME DATA
Net Sales Rs m76,3407,181 1,063.1%  
Other income Rs m35643 836.2%   
Total revenues Rs m76,6967,223 1,061.8%   
Gross profit Rs m14,172947 1,496.6%  
Depreciation Rs m2,6912,543 105.8%   
Interest Rs m1,7894,377 40.9%   
Profit before tax Rs m10,048-5,931 -169.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,028-1,924 -157.4%   
Profit after tax Rs m7,019-4,007 -175.2%  
Gross profit margin %18.613.2 140.8%  
Effective tax rate %30.132.4 92.9%   
Net profit margin %9.2-55.8 -16.5%  
BALANCE SHEET DATA
Current assets Rs m59,09614,335 412.3%   
Current liabilities Rs m40,01849,809 80.3%   
Net working cap to sales %25.0-494.0 -5.1%  
Current ratio x1.50.3 513.1%  
Inventory Days Days75403 18.6%  
Debtors Days Days119171 69.8%  
Net fixed assets Rs m39,07555,432 70.5%   
Share capital Rs m282268 105.3%   
"Free" reserves Rs m30,28113,935 217.3%   
Net worth Rs m42,70314,701 290.5%   
Long term debt Rs m24,8739,478 262.4%   
Total assets Rs m111,02673,988 150.1%  
Interest coverage x6.6-0.4 -1,864.0%   
Debt to equity ratio x0.60.6 90.3%  
Sales to assets ratio x0.70.1 708.5%   
Return on assets %7.90.5 1,583.8%  
Return on equity %16.4-27.3 -60.3%  
Return on capital %17.5-6.4 -272.6%  
Exports to sales %43.325.9 167.1%   
Imports to sales %7.40.2 4,373.4%   
Exports (fob) Rs m33,0441,860 1,776.7%   
Imports (cif) Rs m5,67212 46,494.3%   
Fx inflow Rs m36,9451,860 1,986.5%   
Fx outflow Rs m61,06625 245,344.3%   
Net fx Rs m-24,1221,835 -1,314.6%   
CASH FLOW
From Operations Rs m3,4491,719 200.6%  
From Investments Rs m-8,802-3,148 279.6%  
From Financial Activity Rs m6,9861,426 489.9%  
Net Cashflow Rs m934-3 -27,464.7%  

Share Holding

Indian Promoters % 48.3 33.9 142.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 0.0 -  
FIIs % 34.4 9.9 347.5%  
ADR/GDR % 0.0 16.9 -  
Free float % 10.5 39.3 26.7%  
Shareholders   56,727 21,482 264.1%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   WYETH LTD  PFIZER  NATCO PHARMA  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - SUVEN LIFE COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS